In line with upstream complement inhibition at the C1 level, the use of plasma-derived C1-INH, since long approved and available for the treatment of hereditary angioedema, has been reported in a single patient with cAIHA. The gene discussed is SERPING1; the disease is autoimmune hemolytic anemia, cold type.